LEADER 05136nam 2200925Ia 450 001 9910960031503321 005 20251017110057.0 010 $a9780309527813 010 $a9786610176717 010 $a9781280176715 010 $a1280176717 010 $a9780309527811 010 $a0309527813 035 $a(CKB)111087027010014 035 $a(OCoLC)70749613 035 $a(CaPaEBR)ebrary10049206 035 $a(SSID)ssj0000176892 035 $a(PQKBManifestationID)11165721 035 $a(PQKBTitleCode)TC0000176892 035 $a(PQKBWorkID)10206485 035 $a(PQKB)11347617 035 $a(MiAaPQ)EBC3375900 035 $a(Au-PeEL)EBL3375900 035 $a(CaPaEBR)ebr10049206 035 $a(CaONFJC)MIL17671 035 $a(OCoLC)923259831 035 $a(Perlego)4735258 035 $a(DNLM)1207610 035 $a(BIP)10324219 035 $a(EXLCZ)99111087027010014 100 $a20040218d2004 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aImmunization safety review $einfluenza vaccines and neurological complications /$fImmunization Safety Review Committee, Board on Health Promotion and Disease Prevention ; Kathleen Stratton ... [et al.], editors, Institute of Medicine of the National Academies 205 $a1st ed. 210 $aWashington, D.C. $cNational Academies Press$dc2004 215 $a1 online resource (190 p.) 300 $aBibliographic Level Mode of Issuance: Monograph 311 08$aPrint version: Immunization safety review. Washington, D.C. : National Academies Press, ©2004 0309090865 (OCoLC)54444600 311 08$a9780309090865 311 08$a0309090865 320 $aIncludes bibliographical references. 327 $aFrontMatter -- Reviewers -- Foreword -- Acknowledgments -- Contents -- Executive Summary -- Immunization Safety Review: Influenza Vaccines and Neurological Complications -- THE CHARGE TO THE COMMITTEE -- THE STUDY PROCESS -- THE FRAMEWORK FOR SCIENTIFIC ASSESSMENT -- UNDER REVIEW: INFLUENZA VACCINES AND NEUROLOGICAL COMPLICATIONS -- SCIENTIFIC ASSESSMENT -- SIGNIFICANCE ASSESSMENT -- RECOMMENDATIONS FOR PUBLIC HEALTH RESPONSE -- SUMMARY -- REFERENCES -- Appendixes -- Appendix A Committee Recommendations and Conclusions from Previous Reports -- Appendix B Public Meeting Agenda March 13, 2003 -- Appendix C Chronology of Important Events Regarding Vaccine Safety -- Appendix D Acronyms. 330 $aInfection with the influenza virus can have a serious effect on the health of people of all ages, although it is particularly worrisome for infants, the elderly, and people with underlying heart or lung problems. A vaccine exists (the oeflu shot) that can greatly decrease the impact of influenza. Because the strains of virus that are expected to cause serious illness and death are slightly different every year, the vaccine is also slightly different every year and it must be given every year, unlike other vaccines. The Immunization Safety Review committee reviewed the data on influenza vaccine and neurological conditions and concluded that the evidence favored rejection of a causal relationship between influenza vaccines and exacerbation of multiple sclerosis. For the other neurological conditions studied, the committee concluded the evidence about the effects of influenza vaccine is inadequate to accept or reject a causal relationship. The committee also reviewed theories on how the influenza vaccine could damage the nervous system. The evidence was at most weak that the vaccine could act in humans in ways that could lead to these neurological problems. 606 $aInfluenza vaccines$xSide effects 606 $aNervous system$xDiseases$xImmunological aspects 606 $aImmunization$xComplications 606 $aVaccination$xComplications 606 $aInfluenza Vaccines$xadverse effects$3(DNLM)D007252Q000009 606 $aInfant$3(DNLM)D007223 606 $aVaccination$xadverse effects$3(DNLM)D014611Q000009 606 $aNervous System Diseases$xetiology$3(DNLM)D009422Q000209 606 $aImmunization Schedule$3(DNLM)D007115 606 $aImmune System Diseases$xetiology$3(DNLM)D007154Q000209 606 $aSafety$3(DNLM)D012449 607 $aUnited States 615 0$aInfluenza vaccines$xSide effects. 615 0$aNervous system$xDiseases$xImmunological aspects. 615 0$aImmunization$xComplications. 615 0$aVaccination$xComplications. 615 12$aInfluenza Vaccines$xadverse effects. 615 2$aInfant. 615 2$aVaccination$xadverse effects. 615 22$aNervous System Diseases$xetiology. 615 22$aImmunization Schedule. 615 22$aImmune System Diseases$xetiology. 615 22$aSafety. 676 $a614.5/18 701 $aStratton$b Kathleen R$01797964 712 02$aInstitute of Medicine (U.S.).$bImmunization Safety Review Committee. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910960031503321 996 $aImmunization safety review$94356336 997 $aUNINA